Published in MAbs on March 01, 2011
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | NCT00848926
Worldwide experience with biosimilar development. MAbs (2011) 2.14
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clin Cosmet Investig Dermatol (2015) 1.14
Biosimilar, biobetter and next generation therapeutic antibodies. MAbs (2011) 1.05
Biomarkers in diabetic retinopathy and the therapeutic implications. Mediators Inflamm (2013) 0.97
7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. MAbs (2012) 0.88
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer (2015) 0.83
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
Mabs's communication networks. MAbs (2012) 0.75
Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. Onco Targets Ther (2017) 0.75
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One (2017) 0.75
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2008) 5.94
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2002) 4.11
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol (2010) 3.70
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol (2006) 2.79
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol (2010) 2.44
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature (1995) 2.29
Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol (1997) 2.13
Antibody-based therapeutics to watch in 2011. MAbs (2011) 2.00
Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem (2008) 1.88
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.87
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 1.82
Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem (2008) 1.80
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (2006) 1.77
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol (2009) 1.71
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol (2010) 1.66
Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel (2010) 1.64
New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One (2010) 1.59
Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol (2004) 1.59
Isotype selection in antibody engineering. Nat Biotechnol (2007) 1.57
Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res (2010) 1.51
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood (2008) 1.38
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res (2008) 1.36
Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs (2009) 1.33
Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem (2009) 1.31
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs (2009) 1.30
Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol (2009) 1.30
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res (2010) 1.28
Antibodies against metal chelates. Nature (1985) 1.27
Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel (2010) 1.27
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev (2008) 1.20
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood (2002) 1.20
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. MAbs (2009) 1.20
Preferred CDRH3 lengths for antibodies with defined specificities. Int Immunol (1998) 1.18
Stability of IgG isotypes in serum. MAbs (2010) 1.17
Canakinumab. MAbs (2010) 1.16
Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med (1988) 1.16
The next generation of antibody-drug conjugates comes of age. Discov Med (2010) 1.15
Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol Immunol (2003) 1.08
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol (2009) 1.07
Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci U S A (2004) 1.06
Differential roles of p55 and p75 tumor necrosis factor receptors on stretch-induced pulmonary edema in mice. Am J Physiol Lung Cell Mol Physiol (2007) 1.06
Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry (2008) 1.05
Glutamine-linked and non-consensus asparagine-linked oligosaccharides present in human recombinant antibodies define novel protein glycosylation motifs. J Biol Chem (2010) 1.04
Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins (2004) 1.03
Design of next-generation protein therapeutics. Curr Opin Chem Biol (2010) 1.02
Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem (2010) 0.97
Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Pharm Res (2010) 0.96
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma (2004) 0.95
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. J Cancer Res Ther (2009) 0.94
Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling. Biochemistry (2009) 0.92
Golimumab. MAbs (2009) 0.91
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res (1999) 0.90
G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep (2005) 0.89
5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland. MAbs (2011) 0.87
Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol (2010) 0.86
Studies in serum support rapid formation of disulfide bond between unpaired cysteine residues in the VH domain of an immunoglobulin G1 molecule. Anal Biochem (2009) 0.86
Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur J Biochem (2003) 0.86
A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett (2010) 0.84
Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine. Anal Biochem (2009) 0.83
Rapid and refined separation of human IgG2 disulfide isomers using superficially porous particles. J Sep Sci (2010) 0.82
Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Int J Rad Appl Instrum B (1986) 0.80
Monoclonal antibody hapten radiopharmaceutical delivery. Nucl Med Commun (1986) 0.79
Analysis of identity, charge variants, and disulfide isomers of monoclonal antibodies with capillary zone electrophoresis in an uncoated capillary column. Anal Chem (2010) 0.79
Hydroxyethyl starch antibodies in humans: incidence and clinical relevance. Anesth Analg (1998) 0.78
Bifunctional chelating agents for radiometal-labeled monoclonal antibodies. Cancer Treat Res (1990) 0.77
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland. MAbs (2009) 0.77
Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47
Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol (2010) 3.70
Development trends for therapeutic antibody fragments. Nat Biotechnol (2009) 3.51
Which are the antibodies to watch in 2013? MAbs (2012) 1.56
Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol (2008) 1.53
Future directions for peptide therapeutics development. Drug Discov Today (2013) 1.48
Which are the antibodies to watch in 2012? MAbs (2012) 1.47
Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs (2012) 1.29
Recombinant protein therapeutics--success rates, market trends and values to 2010. Nat Biotechnol (2004) 1.28
Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs (2013) 1.28
Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs (2011) 1.26
Metrics for antibody therapeutics development. MAbs (2010) 1.21
The next generation of antibody-drug conjugates comes of age. Discov Med (2010) 1.15
Antibodies to watch in 2013: Mid-year update. MAbs (2013) 1.13
Current trends in the clinical development of peptide therapeutics. IDrugs (2009) 1.08
Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands. J Pharmacol Exp Ther (2004) 1.03
World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. MAbs (2012) 1.02
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. Expert Opin Drug Discov (2009) 1.01
Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer (2007) 1.01
5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland. MAbs (2011) 0.87
Bispecific antibodies and ADCs: Once and future kings? MAbs (2011) 0.82
Peptides as tools and drugs for immunotherapies. J Pept Sci (2007) 0.81
The amazing, multipurpose antibody. MAbs (2011) 0.78
Pharmacological analysis of a dopamine D(2Short):G(alphao) fusion protein expressed in Sf9 cells. FEBS Lett (2003) 0.78
[Therapeutic antibodies and related products: choosing the right structure for success]. Med Sci (Paris) (2009) 0.78
Endogenous RGS proteins facilitate dopamine D(2S) receptor coupling to G(alphao) proteins and Ca2+ responses in CHO-K1 cells. FEBS Lett (2003) 0.78
Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling. Neuropharmacology (2005) 0.78
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland. MAbs (2009) 0.77
Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014. MAbs (2014) 0.77
Dissimilar pharmacological responses by a new series of imidazoline derivatives at precoupled and ligand-activated alpha 2A-adrenoceptor states: evidence for effector pathway-dependent differential antagonism. J Pharmacol Exp Ther (2003) 0.77
7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. MAbs (2012) 0.76
[Protein scaffolds as alternatives to whole antibodies: from discovery research to clinical development]. Med Sci (Paris) (2009) 0.76
Mabs's communication networks. MAbs (2012) 0.75
Americas Antibody Congress: September 21-23, 2009, Washington, D.C. MAbs (2009) 0.75
Trends in the development of therapeutic anti-cytokine antibodies. Drug Discov Today (2004) 0.75
Letter from the Editor: stratified medicine. MAbs (2011) 0.75
Changes in regulations for approval of therapeutics. MAbs (2014) 0.75
Letter from the editor. MAbs (2009) 0.75
Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor. Eur J Pharmacol (2002) 0.75
mAb therapeutic products and risk management. MAbs (2010) 0.75
Note of appreciation to reviewers. MAbs (2017) 0.75
Editorial for PEDS special issue on antibodies. Protein Eng Des Sel (2010) 0.75
Note of appreciation to reviewers. MAbs (2016) 0.75
Letter from the editor. MAbs (2009) 0.75
Note of appreciation to reviewers. MAbs (2016) 0.75